Tocilizumab, Adipokines and Severe Complications of COVID-19
- PMID: 32661912
- PMCID: PMC7357265
- DOI: 10.1007/s40261-020-00950-2
Tocilizumab, Adipokines and Severe Complications of COVID-19
Conflict of interest statement
The authors declare no competing interests.
Comment in
-
Authors' Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19.Clin Drug Investig. 2020 Sep;40(9):893-895. doi: 10.1007/s40261-020-00948-w. Clin Drug Investig. 2020. PMID: 32661911 Free PMC article. No abstract available.
Comment on
-
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia.Clin Drug Investig. 2020 Jun;40(6):511-518. doi: 10.1007/s40261-020-00917-3. Clin Drug Investig. 2020. PMID: 32337664 Free PMC article. Review.
References
-
- National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. Trial Version 7. Released on March 3, 2020. http://en.nhc.gov.cn/2020-03/29/c_78469.htm. Accessed 13 Jul 2020.
-
- SIMIT Società Italiana di Malattie Infettive e Tropicali. Linee guida sulla gestione terapeutica e di supporto per pazienti con infezione da coronavirus COVID-19. Edizione 2.0, 12 marzo 2020
Publication types
LinkOut - more resources
Full Text Sources
